We propose that another appealing strategy for treating cancers with RAS mutations, as well as many other types of PI3K/Akt1-driven cancers, is the use of PARPi in monotherapy or in combination with chemo- or radiation therapy. This evidence concerns the gene AKT1 and cancer.